Last reviewed · How we verify

nicardipine intravenous — Competitive Intelligence Brief

nicardipine intravenous (nicardipine intravenous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine calcium channel blocker. Area: Cardiovascular.

marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

nicardipine intravenous (nicardipine intravenous) — Haseki Training and Research Hospital. Nicardipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
nicardipine intravenous TARGET nicardipine intravenous Haseki Training and Research Hospital marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
olmesartan medoxomil and a CCB olmesartan medoxomil and a CCB Daiichi Sankyo Co., Ltd. marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type voltage-gated calcium channel
Amlodipine plus Metformin Amlodipine plus Metformin Third Military Medical University marketed Combination therapy: calcium channel blocker + biguanide antidiabetic L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)
nifedipine controlled release tablets nifedipine controlled release tablets Guangzhou First People's Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Eplerenone vs Amlodipine Eplerenone vs Amlodipine Brigham and Women's Hospital marketed Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)
Felodipine add Irbesartan Felodipine add Irbesartan LanZhou University marketed Calcium channel blocker + Angiotensin II receptor blocker combination L-type voltage-gated calcium channels; AT1 angiotensin II receptor
Lacidipine & Amlodipine Lacidipine & Amlodipine Korea University Guro Hospital marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine calcium channel blocker class)

  1. Bayer · 1 drug in this class
  2. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
  3. Haseki Training and Research Hospital · 1 drug in this class
  4. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
  5. Korea University Guro Hospital · 1 drug in this class
  6. Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
  7. Organon and Co · 1 drug in this class
  8. Pfizer Inc. · 1 drug in this class
  9. University Hospital Hradec Kralove · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nicardipine intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/nicardipine-intravenous. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: